Refining the serum miR-371a-3p test for viable germ cell tumor detection: identification and definition of an indeterminate range.


Journal

Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035

Informations de publication

Date de publication:
21 Mar 2023
Historique:
medline: 31 3 2023
entrez: 30 3 2023
pubmed: 31 3 2023
Statut: epublish

Résumé

Circulating miR-371a-3p has excellent performance in the detection of viable (non-teratoma) GCT pre-orchiectomy; however, its ability to detect occult disease is understudied. To refine the serum miR-371a-3p assay in the minimal residual disease setting we compared performance of raw (Cq) and normalized (∆Cq, RQ) values from prior assays, and validated interlaboratory concordance by aliquot swapping. Revised assay performance was determined in a cohort of 32 patients suspected of occult retroperitoneal disease. Assay superiority was determined by comparing resulting receiver-operator characteristic (ROC) curves using the Delong method. Pairwise t-tests were used to test for interlaboratory concordance. Performance was comparable when thresholding based on raw Cq

Identifiants

pubmed: 36993198
doi: 10.21203/rs.3.rs-2644890/v1
pmc: PMC10055551
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : P30 CA142543
Pays : United States
Organisme : NCI NIH HHS
ID : UH3 CA240688
Pays : United States

Commentaires et corrections

Type : UpdateIn

Références

J Clin Oncol. 2019 Nov 20;37(33):3090-3098
pubmed: 31553692
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Sci Rep. 2021 Aug 2;11(1):15582
pubmed: 34341387
Br J Cancer. 2016 Jan 19;114(2):151-62
pubmed: 26671749
Urology. 2007 Mar;69(3):557-9
pubmed: 17382165
Mol Diagn Ther. 2021 May;25(3):273-281
pubmed: 33886084
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Ann Oncol. 2017 Apr 1;28(4):899-902
pubmed: 28137740
Front Oncol. 2022 Dec 08;12:1056823
pubmed: 36568207
Eur Urol Focus. 2021 Sep;7(5):1137-1142
pubmed: 33121935
J Urol. 2021 Jan;205(1):137-144
pubmed: 32856980
J Clin Oncol. 2015 Jan 1;33(1):51-7
pubmed: 25135991
J Clin Oncol. 2010 Feb 1;28(4):531-6
pubmed: 20026808
Eur Urol. 2020 Feb;77(2):290-292
pubmed: 31699528
J Mol Diagn. 2022 Aug;24(8):867-877
pubmed: 35934321
J Urol. 2021 Jun;205(6):1569-1576
pubmed: 33617328

Auteurs

John Lafin (J)

The University of Texas Southwestern Medical Center.

Cinzia Scarpini (C)

University of Cambridge.

Armon Amini (A)

The University of Texas Southwestern Medical Center.

Bendu Konneh (B)

The University of Texas Southwestern Medical Center.

Jeffrey Howard (J)

The University of Texas Southwestern Medical Center.

Thomas Gerald (T)

The University of Texas Southwestern Medical Center.

Michelle Nuno (M)

University of Southern California.

Jin Piao (J)

University of Southern California.

Anna Savelyeva (A)

The University of Texas Southwestern Medical Center.

Zhaohui Wang (Z)

The University of Texas Southwestern Medical Center.

Jeffrey Gagan (J)

The University of Texas Southwestern Medical Center.

Liwei Jia (L)

The University of Texas Southwestern Medical Center.

Cheryl Lewis (C)

The University of Texas Southwestern Medical Center.

Sarah Murray (S)

University of California, San Diego.

Yun Sawa (Y)

University of California, San Diego.

Vitaly Margulis (V)

The University of Texas Southwestern Medical Center.

Solomon Woldu (S)

The University of Texas Southwestern Medical Center.

Douglas Strand (D)

The University of Texas Southwestern Medical Center.

Nicholas Coleman (N)

University of Cambridge.

James Amatruda (J)

University of Southern California.

Lindsay Frazier (L)

Dana-Farber/Boston Children's Cancer and Blood Disorders Center.

Matthew Murray (M)

University of Cambridge.

Aditya Bagrodia (A)

University of California, San Diego.

Classifications MeSH